扎那米韦
神经氨酸酶
神经氨酸酶抑制剂
医学
奥司他韦
药品
病毒学
食品药品监督管理局
病毒
口服
药理学
正粘病毒科
甲型流感病毒
内科学
2019年冠状病毒病(COVID-19)
疾病
传染病(医学专业)
摘要
For many years, antiviral treatment of influenza has consisted of monotherapy with a neuraminidase inhibitor. The Food and Drug Administration (FDA) approved the neuraminidase inhibitors oseltamivir (oral administration) and zanamivir (oral inhalation) in 1999 and peramivir (intravenous administration) in late 2014. These drugs work by binding to the viral neuraminidase protein and interfering with the release of influenza virus particles from infected respiratory tract cells. Neuraminidase inhibitors are FDA-approved for the treatment of uncomplicated influenza within 2 days after onset in outpatients, on the basis of randomized, controlled trials, but they are also recommended for the treatment of patients with . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI